Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

NCT01234766 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Follicular

Interventions

DRUG: Bendamustine
DRUG: Rituximab
RADIATION: Y-90 ibritumomab

Sponsor

Dartmouth-Hitchcock Medical Center

Collaborators

[object Object]
[object Object]